The hot wind of industrial marijuana has spread to many pharmaceutical enterprises in China, which are stepping up the layout

[industry trends of China Pharmaceutical network] the so-called industrial hemp refers to the hemp varieties with toxicity removed and THC content less than 0.3%, which are not worthy of drug use, and the raw materials extracted from industrial hemp can be widely used in medicine, food, textile, construction and other fields It is reported that CBD (cannabinoids) contained in industrial marijuana are widely used in medicine At present, industrial marijuana is becoming a new industry hotspot in the world, and this industrial marijuana hot wind originated in North America has spread to China In this context, many domestic pharmaceutical companies are stepping up their layout According to tianyancha statistics, up to now, there are more than 190 enterprises in the domestic business scope including "industrial marijuana" The industry believes that the domestic industrial cannabis industry space is expected to grow further, and in the context of a large price reduction of many drugs, many pharmaceutical companies in the layout hope to bring new profits to pharmaceutical companies Longjin Pharmaceutical Co., Ltd announced on the evening of February 28 that it plans to increase the capital of Yunnan Muya agricultural science and Technology Co., Ltd by no more than 15 million yuan and acquire 51% of its equity The latter's main business is large-scale cultivation of industrial marijuana Longjin pharmaceutical said that the application prospect of industrial hemp extract is broad, and the demand for hemp extract such as cannabis diphenol (CBD, c21h30o2) in the international market is in the ascendant According to the bright field group, the global hemp diphenol industry value will reach 5.7 billion US dollars in 2019 and 18.1 billion US dollars in 2021; in 2017, the market scale of China's Hemp diphenol industry is only 448 million yuan Longjin pharmaceutical hopes to enter the industrial marijuana market through planting business, layout local advantageous industries as soon as possible, seize the opportunity of industrial development, and bring new profit growth points through foreign investment On January 12, 2019, Kangenbei's affiliated company Xikang biology signed a contract with China Macquarie Technology Co., Ltd., covering the cultivation, extraction technology, production and processing of industrial marijuana Both sides will jointly explore and promote the market development and industrial development of industrial marijuana products On January 28, Kangenbei announced that Yunnan Yunxing, the second level wholly-owned subsidiary, had received the letter from Luxi County Public Security Bureau on the application for approval of Yunnan Yunxing Biotechnology Co., Ltd.'s project of processing big twist leaves The company will do processing technology research and product research and development on the extracts of cannabinoids (CBD) and other active ingredients in industrial marijuana to seek new profit growth point for the company In January 2019, Zixin pharmaceutical issued an announcement that Jilin Academy of Agricultural Sciences and fytagoras B.V., a wholly-owned subsidiary of the company, signed the industrial marijuana cooperative research agreement The two sides formally established a cooperative R & D relationship, with the goal of "the CBD content of marijuana varieties is up to 10%" Galaxy biology in January 2019, Galaxy biology also said on the interactive platform that the company holds 5.55% of the equity of sinobio, and sinobio has obtained the domestic industrial hemp leaves processing license, and its overseas participating subsidiary has obtained the Kentucky hemp processing license According to the industry, in the field of agriculture, part of the "planting license" has limited value, and more valuable is the "processing license" It is expected that galaxy biology will usher in more development opportunities and markets in the future Although the domestic industrial leprosy is more and more hot, some industry analysts believe that the current situation of industrial cannabis industry in China is still in the early stage of development can not be ignored, and its development prospects and directions are difficult to make accurate prediction at present, so the layout of enterprises are still facing uncertainty risks.